Prostatic Hyperplasia
Conditions
Keywords
benign prostatic hyperplasia,, AVODART,, FLOMAX
Brief summary
This study will be an open-label, randomized, single dose, three way partial crossover study in healthy male subjects. The aim of the study is to evaluate bioequivalence of a fixed dose combination (FDC) capsule of dutasteride and tamsulosin hydrochloride (HCl) (0.5 milligram \[mg\]/0.4 mg) relative to co-administration of dutasteride 0.5 mg capsules and tamsulosin hydrochloride 0.4 mg tablets in both the fed and fasted states. Approximately 98 healthy adult male subjects will be enrolled into the study. Subjects will receive single oral doses in 3 treatment periods and be randomized to one of twelve different treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) wherein A= commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state, B= fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state, C= commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state, D= fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state. Each treatment period will be separated by a minimum 28 day washout period. The total duration of a subject's involvement in this study is approximately 15-18 weeks.
Detailed description
An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART 0.5mg and FLOMAX 0.4mg Commercial Capsules in Healthy Male Subjects
Interventions
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
DRUGTreatment sequence D
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects defined as individuals who are free from clinically significant illness or disease as determined by the investigator based on their medical history, physical examination, laboratory studies, ECGs, and other tests. * Males who are 18 - 45 years of age, inclusive. * Weight range 55 - 95 kg (inclusive) and body mass index 19 - 30 kg/m2 (inclusive). * Willing and able to give written informed consent, willing to participate for the full duration of the study, and able to understand and follow instructions related to study procedures
Exclusion criteria
* Slow metabolizer for CYP2D6 as determined by screening PGx analysis. * History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal reactions or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury. * Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer, such as St. John's Wort) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety. * Chronic hepatitis B and C, as evidence by positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody. * Positive HIV test at screening. * History of sensitivity to heparin or heparin-induced thrombocytopenia. * History of regular alcohol consumption exceeding 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening. Subjects must be able and willing to abstain from beverages and foods containing alcohol 24 hours prior to and during the dosing day. * A positive urine drug or alcohol (Breath test or urine) screen result at screening or check-in.. * The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication or anytime during the study period. * Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period. * History or presence of allergy, intolerance, or contraindication to tamsulosin HCl or AVODART or drugs of this class, or a history of drug or other allergy (including true sulfonamide allergy) that, in the opinion of the physician responsible, contraindicates their participation. * Subjects who have consumed the following foods or drinks within 7 days prior to the first dose of study medication or at any time during the clinical phase of the study: grapefruit juice; red wine; grapefruit or cruciferous vegetables (watercress, broccoli, cabbage, Brussels sprouts). * QTc ≥ 450 msec at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration maximum (Cmax) of plasma dutasteride in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve from time zero to infinity (AUC[0-inf]) of plasma tamsulosin in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Concentration maximum (Cmax) of plasma tamsulosin in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma dutasteride in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 72 hours (AUC[0-72]) of plasma dutasteride in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Concentration maximum (Cmax) of plasma dutasteride in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma tamsulosin in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve from time zero to infinity (AUC[0-inf]) of plasma tamsulosin in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Concentration maximum (Cmax) of plasma tamsulosin in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma dutasteride in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 72 hours (AUC[0-72]) of plasma dutasteride in fasted state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma tamsulosin in fed state | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to maximum observed plasma drug concentration (tmax) of tamsulosin and dutasteride | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Elimination half-life (t1/2) of tamsulosin and dutasteride | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Negative slope of the terminal phase of tamsulosin and dutasteride | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
| Number of subjects with adverse event (AE) and serious adverse event (SAE). | Up to 18 weeks | AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement will be categorized as SAE. |
| Number of subjects with abnormal clinical laboratory parameters | Up to 18 weeks | Blood samples will be collected to analyze aspartate aminotransferase (AST), alkaline Phosphatase (ALP), alanine aminotransferase (ALT), creatinine, blood urea nitrogen, creatine kinase, total bilirubin, direct bilirubin, total protein, albumin, glucose, sodium, potassium, calcium |
| Number of subjects with abnormal hematology laboratory parameters | Up to 18 weeks | Blood samples will be collected to analyze White Blood Cells (WBC), neutrophils, basophils, eosionophils, lymphocytes, monocytes, Red Blood Cells (RBC) count, RBC indices, Day -1average red blood cell size (MCV), hemoglobin amount per red blood cell (MCH) hemoglobin, hematocrit, and platelet count |
| Number of subjects with abnormal urinalysis | Up to 18 weeks | Urine samples will be collected to analyze specific gravity, pH, glucose, protein, blood and ketones |
| Blood pressure assessment as a measure of safety | Up to 18 weeks | Systolic and diastolic blood pressure will be measured in a supine position at pre-dose, Days 2, 3, 4,5,6,7,43 and 85 post-dose |
| Measurement of pulse rate as a measure of safety | Up to 18 weeks | Pulse rate will be measured in a supine position at pre-dose, Days 2, 3, 4,5,6,7,43 and 85 post-dose |
| Concentration minimum (Cmax) of plasma tamsulosin | Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs | Plasma samples will be collected at indicated time points |
Countries
United States
Outcome results
None listed